|Bid||103.85 x 1400|
|Ask||104.02 x 800|
|Day's Range||103.09 - 107.67|
|52 Week Range||84.45 - 278.62|
|Beta (3Y Monthly)||1.57|
|PE Ratio (TTM)||3.40|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||196.20|
Ligand Pharmaceuticals Inc. disclosed Thursday that a new program to repurchase up to $500 million worth of stock over the next three years was approved by the company's board. Based on Wednesday's stock closing price of $91.80, the biopharmaceutical company could buy back up to 5.45 million shares, or 28.6% of the shares outstanding as of Aug. 7. The company said its previous $350 million stock repurchase program was terminated after it had bought back 2.97 million shares for about $350 million. Separately, Ligand disclosed that it had entered into a commercial platform license agreement with Hong Kong-based Kira Pharmaceuticals, which is focused on treatments for immunological diseases and cancer immunotherapy, in which Kira will be able to use OmniAb platform rodents and birds to discover fully human mono- and bispecific antibodies. Ligand will be eligible to receive milestone payments and tiered royalties for each product delivering an OmniAb antibody. The stock, which was still inactive in premarket trading, has slumped 32.4% year to date while the S&P 500 has gained 19.7%.
Ligand Pharmaceuticals Incorporated announces that the company is scheduled to participate in the H.C. Wainwright 21st Annual Global Investment Conference in New York City.
In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.
Ligand Pharmaceuticals Incorporated (LGND) partner CASI Pharmaceuticals, Inc. (CASI), a U.S. biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, the U.S., and throughout the world, announces the official product launch of melphalan hydrochloride for injection (EVOMELA) in China which is the first commercial product launch for CASI. Melphalan hydrochloride for injection (EVOMELA) received market approval by the China National Medical Products Administration (NMPA) for use as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
CEO of Ligand Pharmaceuticals Inc (30-Year Financial, Insider Trades) John L Higgins (insider trades) bought 1,850 shares of LGND on 07/31/2019 at an average price of $95.45 a share. Continue reading...
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) shares are down 10.5% on Tuesday following the company’s earnings report, but one of the company’s most vocal critics and short sellers is leaning into its bearish trade. On Tuesday, Ligand short seller Lemelson Capital Management said the firm has been adding to its short position against Ligand and is calling for an investigation into alleged crimes committed by the company. “Sadly, investors have been ruined by Ligand’s alleged scheme while the SEC has ignored the red flags and botched opportunities for a proper investigation of the company,” Lemelson Capital’s Chief Investment Officer Fr.
Ligand (LGND) delivered earnings and revenue surprises of 11.48% and 9.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Short position in Ligand pharmaceuticals, long position in Geospace Technologies, contribute to 70.27 percent net return in 1H, 2019 SHELBURNE, Vt ., July 16, 2019 /PRNewswire/ -- Lemelson Capital Management, ...
How far off is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) from its intrinsic value? Using the most recent...
Ligand Pharmaceuticals Inc NASDAQ NMS:LGNDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for LGND with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting LGND. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding LGND totaled $64.13 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SQ Innovation will use Ligand's Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure. The smaller delivery volume enables use of established drug container and device technology developed for insulin and other biologics, resulting in faster development and reduced cost. SQ Innovation to use advanced 3 mL drug delivery platform by Sensile Medical AG, a Gerresheimer company, for the novel treatment.